

Novocure (NVCR) overview

Wedbush PacGrow Healthcare Conference
August 15, 2018

patientforward



forward-looking statements

This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and objectives, including with respect to the development and commercialization of its lead product candidate, Optune, for a number of oncology indications. These forward-looking statements can be identified in this presentation by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words “expect”, “intend”, “anticipate”, “plan”, “may”, “should”, “would”, “could” or other words of similar meaning. These statements are based on assumptions and assessments made by Novocure in light of industry experience and perception of historical trends, current conditions, expected future developments and other appropriate factors. By their nature, forward-looking statements involve risk and uncertainty, and Novocure’s performance and financial results could differ materially from those expressed or implied in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2018, or in subsequent quarterly filings with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation. Novocure assumes no obligation to update or correct the information contained in this presentation, whether as a result of new information, future events or otherwise, except to the extent legally required.

The statements contained in this presentation are made as at the date of this presentation, unless some other time is specified in relation to them, and service of this presentation shall not give rise to any implication that there has been no change in the facts set out in this presentation since such date. Nothing contained in this presentation shall be deemed to be a forecast, projection or estimate of the future financial performance of Novocure, except where expressly stated.

As of the date of this presentation, Optune is only FDA-approved for the treatment of adults with supratentorial glioblastoma, or GBM, and its approval for other indications is not certain. Novocure can provide no assurances regarding market acceptance of Optune or its successful commercialization, and can provide no assurances regarding the company’s results of operations or financial condition in the future. This presentation is for informational purposes only and may not be relied upon in connection with the purchase or sale of any security.

Optune® indications for use and important safety information

INDICATIONS

- Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
- Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.
- For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

CONTRAINDICATIONS

- Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.
- Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Optune® indications for use and important safety information

WARNINGS AND PRECAUTIONS

- Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).
- Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.
- The most common ($\geq 10\%$) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.
- The most common ($\geq 10\%$) adverse events seen with Optune monotherapy were medical device site reaction and headache.
- The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.
- Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.
- If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

novocure™

a global oncology company
with a proprietary platform

GROWING COMMERCIAL BUSINESS

- More than 2,100 patients on therapy
- 14 consecutive quarters of patient growth
- \$217 million trailing twelve month revenues


SIGNIFICANT UPSIDE POTENTIAL

- Increase adoption and average reimbursement in GBM
- Advance clinical pipeline in five additional solid tumor indications


Information above as of June 30, 2018

we can leverage physics to fight cancer

AN ELECTRIC FIELD EXERTS FORCES ON CHARGED OBJECTS



TUMOR TREATING FIELDS DESCRIBES ELECTRIC FIELDS THAT ALTERNATE 100,000 TO 300,000 TIMES PER SECOND TO TARGET CANCER CELLS



TUMOR TREATING FIELDS USES ELECTRIC FIELDS TO DISRUPT CELL DIVISION



MISALIGNED TUBULINS INTERFERE WITH FORMATION OF MITOTIC SPINDLE



ALTERNATING ELECTRIC FIELDS DISRUPT CANCER CELL DIVISION




MISALIGNED SEPTINS INTERFERE WITH FORMATION OF CONTRACTILE RING



CANCER CELL DEATH

single therapy provides multiple opportunities in solid tumor cancers



the Optune® system

ELECTRIC FIELD GENERATOR



The portable field generator can be carried with you to generate Tumor Treating Fields as you go about your day.

Sterile, single-use transducer arrays are connected to the electric field generator to deliver therapy. Transducer arrays should be changed at least 2 times per week (every 4 days at most).


TRANSDUCER ARRAY



Steve is an Optune user

In newly diagnosed GBM,


Optune plus temozolomide provided an unprecedented long-term survival benefit



- Survival with Optune plus TMZ versus TMZ alone was significantly better at the 2- and 5-year landmark analyses
- Median overall survival in ITT population significantly extended – by nearly 5 months (p<0.001)
- Optune plus TMZ also significantly improved PFS versus TMZ alone

GBM, glioblastoma; TMZ, temozolomide; PFS, progression-free survival; ITT, intent-to-treat
1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA*. 2017;318(23):2306-2316. **2.** Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized-clinical trial. *JAMA Oncol* 2018;4(4):495-504.

more time on Optune predicted increased significant survival benefit





86% of patients received a survival benefit from Optune because they used it more than half the time (n=388/450)

Based on amount of time Optune was turned on and providing therapy over the course of a month. This data reflects the average patient usage of Optune for the first 6 months of treatment (months 1-6).

†Approximation, based on monthly usage.
‡vs TMZ alone.


TMZ, temozolomide
Ram Z, Kim CY, Nicholas GA and Toms S on behalf of EF-14 investigators. Compliance and treatment duration predict survival in a phase 3 EF-14 trial of Tumor Treating Fields with temozolomide in patients with newly diagnosed glioblastoma. Presented at: 2017 Society for Neuro Oncology; November 16-19, 2017; San Francisco, CA. Oral presentation ACTR-27.

five-year survival analysis in most compliant patients (>90%)¹



1. Ram Z, Kim CY, Nicholas GA and Toms S on behalf of EF-14 investigators. Compliance and treatment duration predict survival in a phase 3 EF-14 trial of Tumor Treating Fields with temozolomide in patients with newly diagnosed glioblastoma. Presented at: 2017 Society for Neuro Oncology; November 16-19, 2017; San Francisco, CA. Oral presentation ACTR-27.

established commercial operations in six markets across three regions




Information above as of June 30, 2018

†Considers currently active markets: Germany, Switzerland, Austria and Israel

continued growth in active patients

active patients at period end



14

CONSECUTIVE QUARTERS OF ACTIVE PATIENT GROWTH SINCE INITIAL PRESENTATION OF EF-14 DATA

8,000+

PATIENTS TREATED TO DATE GLOBALLY

record quarterly revenue of \$61.5 million

global net revenues (USD in thousands)



60%

YEAR-OVER-YEAR REVENUE GROWTH Q2 2018 VS. Q2 2017

\$217

MILLION TRAILING TWELVE MONTH REVENUES

multiple levers for revenue growth in GBM

OPPORTUNITY TO INCREASE GBM PENETRATION

- Category 1 NCCN guidelines® recommendation
- Steady growth in prescriptions for newly diagnosed GBM




OPPORTUNITY TO INCREASE NET REVENUES REALIZATION

- Step-function improvements with national reimbursements, e.g. Medicare
- Incremental improvements with ongoing market access initiatives

OPPORTUNITY TO STRATEGICALLY EXPAND INTO ADDITIONAL MARKETS OVER TIME

- Current commercial efforts focused on six markets
- Ability to leverage established organization across three regions

advancing clinical pipeline



robust intellectual property portfolio

INTELLECTUAL PROPERTY

- As of December 31, 2017 over

140

issued patents globally with expected expiration dates as late as 2035

- Numerous patents pending worldwide

LAYERED PATENT STRATEGY

- Hold fundamental IP for the use of alternating electric fields in oncology
- Platform technology, tools and multiple applications covered, including mechanism of action, use of alternating electric fields in combination with chemotherapy and delivery of alternating electric fields through transducer arrays
- Continue to file patent applications globally as we enhance our technology and applications

PMA PATHWAY A BARRIER TO COMPETITION

- Optune® classified as class III, life-sustaining device requiring PMA
- Anticipate any competitor device would require clinical trials and extensive data

novocure[™]
patientforward

